Log In
Print
BCIQ
Print
Print this Print this
 

Mongersen (GED-0301)

  Manage Alerts
Collapse Summary General Information
Company Nogra Pharma Ltd.
DescriptionAntisense oligonucleotide targeting SMAD family member 7 (MADH7; SMAD7)
Molecular Target SMAD family member 7 (MADH7) (SMAD7)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase II
Standard IndicationCrohn's disease
Indication DetailsTreat moderate to severe Crohn's disease (CD)
Regulatory Designation
Partner Celgene Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,610.0M

$710.0M

$1,900.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today